As pointed by the Coordination for the National Policy for Blood and blood, in the 2007 year, Brazil had 8.168 registered patients, of whom 6.885 were patients with Hemophilia A and 1.283 patients with Hemophilia B. This disease is characterized by a hereditary bleeding disorder due to defect in the X chromosome, which leads the patient to a predisposition to uncontrollable bleeding, internal or external, in different regions of the body. The treatment of this pathological process is complex due to deficiency of a clotting protein, which affects many body systems, complexity is reflected also in the ability of psycho-social adjustment. For this, we believe that providing a source of stem cells as therapy is an option to alleviate the problems caused by this disease. Providing a likely source of stem cells is the yolk sac, which, during development in mammals, the first home blood cells, the erythrocytes, which express the transcription factors that specify these hematopoietic cells to their destination. Thus, the objective of this work will characterize the hematopoietic stem cells of yolk sac of sheep in order to focus on the ability hematogenic the same in different gestational ages, wishing to contribute to the advancement in the treatment of this disease, using a source of stem cells in order to provide support for future cell therapy.
News published in Agência FAPESP Newsletter about the scholarship: